NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 1995-.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].
Show detailsBibliographic details: Wang L, Kourtis AP, Ellington S, Legardy-Williams J, Bulterys M. Safety of tenofovir during pregnancy for the mother and fetus: a systematic review. Clinical Infectious Diseases 2013; 57(12): 1773-1781. [PubMed: 24046310]
Abstract
Tenofovir disoproxil fumarate (TDF) safety during pregnancy has important public health implications. This review summarizes TDF safety during pregnancy, focusing on pregnancy outcomes, congenital anomaly risk, and other potential toxicities on neonates. Although information is limited, TDF appears to be safe during pregnancy. In 6 studies of human immunodeficiency virus type 1 (and/or hepatitis B virus)-infected women receiving TDF during pregnancy, adverse events were mild to moderate; none were considered to be TDF-related. Five studies that followed in utero TDF-exposed infants showed no increased risk of growth or bone abnormalities. One study showed slightly lower infant height at age 1 year, but the significance is unclear. The Antiretroviral Pregnancy Registry database, with 1800 pregnancies exposed to TDF in the first trimester, does not indicate increased congenital anomaly risk with TDF exposure. More evidence collected prospectively, ideally with bone density measurements and randomized trial design, will be optimal to determine the effects of antenatal TDF exposure on children's health.
- Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.[PLoS Med. 2012]Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.Gibb DM, Kizito H, Russell EC, Chidziva E, Zalwango E, Nalumenya R, Spyer M, Tumukunde D, Nathoo K, Munderi P, et al. PLoS Med. 2012; 9(5):e1001217. Epub 2012 May 15.
- Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants.[AIDS. 2012]Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants.Siberry GK, Williams PL, Mendez H, Seage GR 3rd, Jacobson DL, Hazra R, Rich KC, Griner R, Tassiopoulos K, Kacanek D, et al. AIDS. 2012 Jun 1; 26(9):1151-9.
- Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus.[J Hepatol. 2014]Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus.Greenup AJ, Tan PK, Nguyen V, Glass A, Davison S, Chatterjee U, Holdaway S, Samarasinghe D, Jackson K, Locarnini SA, et al. J Hepatol. 2014 Sep; 61(3):502-7. Epub 2014 May 5.
- Review Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.[Clin Infect Dis. 2010]Review Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Clin Infect Dis. 2010 Sep 1; 51(5):496-505.
- Review Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding.[AIDS. 2017]Review Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding.Mofenson LM, Baggaley RC, Mameletzis I. AIDS. 2017 Jan 14; 31(2):213-232.
- Safety of tenofovir during pregnancy for the mother and fetus: a systematic revi...Safety of tenofovir during pregnancy for the mother and fetus: a systematic review - Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews
Your browsing activity is empty.
Activity recording is turned off.
See more...